Literature DB >> 26864152

Years of life that could be saved from prevention of hepatocellular carcinoma.

A Cucchetti1, F Trevisani1, L Bucci1, M Ravaioli1, F Farinati2, E G Giannini3, F Ciccarese4, F Piscaglia1, G L Rapaccini5, M Di Marco6, E Caturelli7, M Zoli1, F Borzio8, R Sacco9, M Maida10, M Felder11, F Morisco12, A Gasbarrini5, S Gemini13, F G Foschi14, G Missale15, A Masotto16, A Affronti10, M Bernardi1, A D Pinna1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. AIM: To assess how many years of life are lost after HCC diagnosis.
METHODS: Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables.
RESULTS: Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18-61 years) had the highest number of years-of-life lost, representing approximately 41% of the overall benefit obtainable from prevention. Advancements in HCC management have progressively reduced the number of years-of-life lost from 12.6 years in 1986-1999, to 10.7 in 2000-2006 and 7.4 years in 2007-2014. Currently, an HCC diagnosis when a single tumour <2 cm results in 3.7 years-of-life lost while the diagnosis when a single tumour ≥ 2 cm or 2/3 nodules still within the Milan criteria, results in 5.0 years-of-life lost, representing the loss of only approximately 5.5% and 7.2%, respectively, of the entire lifespan from birth.
CONCLUSIONS: Hepatocellular carcinoma occurrence results in the loss of a considerable number of years-of-life, especially for younger patients. In recent years, the increased possibility of effectively treating this tumour has improved life expectancy, thus reducing years-of-life lost.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26864152     DOI: 10.1111/apt.13554

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

1.  Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?

Authors:  Federico Piñero; Fernando Rubinstein; Sebastián Marciano; Nora Fernández; Jorge Silva; Yanina Zambelo; Margarita Anders; Alina Zerega; Ezequiel Ridruejo; Carlos Miguez; Beatriz Ameigeiras; Claudia D'Amico; Luis Gaite; Carla Bermúdez; Carlos Rosales; Gustavo Romero; Lucas McCormack; Virginia Reggiardo; Luis Colombato; Adrián Gadano; Marcelo Silva
Journal:  Dig Dis Sci       Date:  2018-12-03       Impact factor: 3.199

Review 2.  Prevention of Hepatocellular Carcinoma.

Authors:  Kerstin Schütte; Fathi Balbisi; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2016-08-18

3.  Digestive cancer screening across Europe.

Authors:  Patrizia Burra; Michael Bretthauer; Maria Buti Ferret; Ana Dugic; Pierluigi Fracasso; Marcis Leja; Tamara Matysiak Budnik; Patrick Michl; Luigi Ricciardiello; Thomas Seufferlein; Monique van Leerdam; Andreea Botos
Journal:  United European Gastroenterol J       Date:  2022-04-26       Impact factor: 6.866

4.  Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States.

Authors:  James M Paik; Pegah Golabi; Rakesh Biswas; Saleh Alqahtani; Chapy Venkatesan; Zobair M Younossi
Journal:  Hepatol Commun       Date:  2020-04-04

5.  Influence of Demographic Factors on Long-Term Trends of Premature Mortality and Burden Due to Liver Cancer: Findings From a Population-Based Study in Shanghai, China, 1973-2019.

Authors:  Zheng Luo; Yongbin Zou; Jiaxin Xie; Hui Cao; Yichen Chen; Yibo Ding; Xiaopan Li; Yang Deng; Lile Wu
Journal:  Front Public Health       Date:  2022-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.